sutimlimab
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cold Agglutinin Disease
Conditions
Cold Agglutinin Disease
Trial Timeline
Nov 11, 2021 → Nov 15, 2022
NCT ID
NCT05132127About sutimlimab
sutimlimab is a phase 3 stage product being developed by Sanofi for Cold Agglutinin Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05132127. Target conditions include Cold Agglutinin Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05132127 | Phase 3 | Completed |
Competing Products
20 competing products in Cold Agglutinin Disease